ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO1108

SARS-CoV-2 Vaccination Reduces the Frequency of Acute Kidney Disease in COVID-19 Patients: A Prospective Multicenter Multinational Study

Session Information

  • COVID-19 - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Lombardi, Raul, Universidad de la Republica Facultad de Medicina, Montevideo, Montevideo, Uruguay
  • Ferreiro, Alejandro, Universidad de la Republica Facultad de Medicina, Montevideo, Montevideo, Uruguay
  • Venegas justiniano, Joanna Yanissa, Corporacion Arzobispo Loayza SAC, Lima, Peru
  • Pereira, Mariana B., Universidade de Sao Paulo, Sao Paulo, Brazil
  • Carlino, Maria Cristina, Circulo Medico de Rosario, Santa Fe, Rosario, Argentina
  • Claure-Del Granado, Rolando, Universidad Mayor de San Simon, Cochabamba, Cochabamba, Bolivia, Plurinational State of
  • Ponce, Daniela, Universidade Estadual Paulista Julio de Mesquita Filho, Sao Paulo, SP, Brazil
  • Zinoveev, Maria Agustina, Universidad de la Republica Facultad de Medicina, Montevideo, Montevideo, Uruguay

The development of renal alterations in SARS-CoV-2 infection is frequent and is associated with poor outcome.
Objectives. To evaluate AKD (proteinuria, hematuria, AKI) and the impact of immunization with vaccine for the acquisition of kidney complications of the disease.


Observational, prospective, multicenter, multinational, longitudinal study. Inclusion criteria: patients ≥ 18 years with COVID-19 by RT-PCR who required hospital admission between march 2021 and may 2022. Patients receiving KRT, or CKD stage 4 - 5 were excluded. Data collected in electronic web form. Approved by the Ethics Committee. H0 was rejected with a p value <0.05.


360 patients from 5 countries: Peru (45%), Brazil (22.5%), Bolivia (14.7%), Argentina (11.1%), Uruguay (6.7%). 57.7% male. Age 62 (48-75) years. Comorbidities: hypertension (49.7%), diabetes (31.8%) obesity (26.3%). 73.8% were hospitalized in a conventional ward, 15.6% in the ICU and 10.6% in the emergency room. At admission: Scr 0.86 (0.68-1.07) mg/dl, proteinuria 225 patients (62.5%); (27,4% developed at evolution). 36,4% developed AKI, most of them KDIGO stage 3 (47.9%) KRT (37.4%). Diuresis preserved in 71.4%. Complete recovery 40.2%, partial 12.4% and 47.4% had no recovery. 50.9% were admitted to the ICU and 163 (45.3%) received mechanical ventilation. 56.2% developed sepsis. In-hospital mortality was 30.2%. Mortality was analyzed according 4 groups: 1) without proteinuria or AKD ( 5,8%); 2) proteinuria without AKI (24,1%) ; 3) AKI withot proteinuria or hematuria (36,4%) ; 4) proteinuria and AKI (55,5%) (p< 0.0001). Patients who received at least one dose of SARS CoV-2 vaccine had lower frequency of proteinuria (52 vs 71.8% p<0.001), hematuria (24.4 vs 44.4%, p<0.01), AKI (42 vs 47.1%, p<0.05) and mortality adjusted for comorbid factors (25 vs 44.5%, p<0.001).


The epidemiological profile of COVID associated AKD in Latin America was similar to previous reports. Isolated proteinuria was the most frequent manifestation of AKD. Mortality of AKD was maximal in AKI associated with proteinuria. Vaccination against SARS CoV-2 decreased the frequency of AKD, and was associated with a decrease in mortality.